Abstracts tagged "quality improvement"

Abstract Number: 304 • 2019 ACR/ARP Annual Meeting
The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017
Zara Izadi¹, Gabriela Schmajuk ², Julia Kay ³, Michael Evans ¹ and Jinoos Yazdany ³, ¹UCSF Division of Rheumatology, San Francisco, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: The ACR’s Rheumatology Informatics System for Effectiveness (RISE) is an EHR‐enabled registry that represents over 36% of the U.S. clinical rheumatology workforce and calculates…
Abstract Number: 1862 • 2019 ACR/ARP Annual Meeting
Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making
Eric Newman¹, Jonida Cote ¹ and Joseph Chronowski ¹, ¹Geisinger, Danville, PA
Background/Purpose: Treat to Target (T2T) opportunities and rheumatologist decision making are not defined, captured, or reportable within existing electronic health record (EHR) software. We developed…
Abstract Number: 311 • 2019 ACR/ARP Annual Meeting
Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project
Melissa DeFoe¹, Rabih Nayfe ², Una Makris ³, Rashmi Arora ³ and Swathi Reddy ³, ¹VA North Texas Health Care System, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern Medical Center and the VA North Texas Health Care System, Dallas, TX
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of osteopenia and osteoporosis, which may result in fragility fractures and significant cost and morbidity. …
Abstract Number: 1863 • 2019 ACR/ARP Annual Meeting
Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients
Heena Sheth¹, Grimes Vera ², Diana Rudge ², Gary Fischer ², Larry W. Moreland ¹ and Rohit Aggarwal ³, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, ³University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: To improve Pneumococcal Vaccination rates in high risk Rheumatology patients on immunosuppressive therapy.Methods: The study was a quality improvement project based on the pre-post-intervention…
Abstract Number: 317 • 2019 ACR/ARP Annual Meeting
Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative
Vy Do¹, MaiLan Nguyen ¹, Keiji Akamine ², Julie Fuller ¹, Lorien Nassi ¹, Tracey Wright ³ and Katie Stewart ¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, ³University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX
Background/Purpose: Mycophenolate is widely prescribed in the rheumatology setting. However, usage of mycophenolate during the first trimester of pregnancy is associated with an increased risk…
Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Fatima Barbar-Smiley¹, Stephanie Lemle ¹, Cagri Yildirim-Toruner ¹, Edward Oberle ¹, Darby McDonald ¹, Vidya Sivaraman ² and Stacy Ardoin ¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…
Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Francine Castillo¹, Michael Dodge ¹, Jung Hee Noh ², Laura Trupin ¹, Jinoos Yazdany ³ and Sarah Goglin ³, ¹University of California, San Francisco, San Francisco, CA, ²Zuckerberg San Francisco General Hospital, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…
Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Eric Liu¹ and Andras Perl ², ¹SUNY Upstate University Medical Center, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
Abstract Number: 319 • 2019 ACR/ARP Annual Meeting
A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine
Milena Gianfrancesco¹, Sara Murray ¹, Michael Evans ², Gabriela Schmajuk ³ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although generally well tolerated, the long-term use of hydroxychloroquine (HCQ) may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology…
Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Leanna Wise¹, Stavros Savvas ² and Elizabeth Ortiz ², ¹LAC+USC/Keck Medicine of USC, Los Angeles, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Kelly Corbitt ¹, Isis Lopez² and David Dillon ³, ¹University of Miami/Jackson Memorial Hospital, Miami, FL, ²University of Miami/ Jackson Memorial Hospital, Miami, FL, ³University of Miami/Jackson Memorial Hospital, Miami
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…
Abstract Number: 1126 • 2019 ACR/ARP Annual Meeting
A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
Sarah French¹, Joshua Ng ¹, Darlene Young ², Michael Evans ³, Tobias Schmelzinger ¹, Gabriela Schmajuk ⁴, Jinoos Yazdany ⁵ and Andrew Gross ¹, ¹UCSF, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁵UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing osteoporosis as compared to the general population, even after controlling for glucocorticoid use[1]. Identification…
Abstract Number: 1136 • 2019 ACR/ARP Annual Meeting
Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
Richard Zamore¹, ¹Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: No shows are a widespread problem across medical practices, and lead to negative consequences for patients and providers (Mendel 2017). The rheumatology division at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].